|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
29,990,000 |
Market
Cap: |
2.65(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0.062 - $1.22 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Atreca is a clinical-stage biopharmaceutical company utilizing its platform to discover and develop antibody-based immunotherapeutics to treat a range of solid tumor types. Co.'s primary product candidate, ATRC-101, is a monoclonal antibody with a mechanism of action and target derived from an antibody identified using its discovery platform. ATRC-101 reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal and breast cancer samples from multiple patients. Co. owns worldwide rights to ATRC-101.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
1 |
1 |
1 |
1 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
1 |
1 |
1 |
1 |
Total Buy Transactions |
1 |
1 |
1 |
1 |
Total Shares Sold |
20,788 |
20,788 |
353,058 |
410,690 |
Total Sell Value |
$1,455 |
$1,455 |
$144,635 |
$250,581 |
Total People Sold |
1 |
1 |
6 |
6 |
Total Sell Transactions |
1 |
1 |
9 |
14 |
End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Cross Herb |
Chief Financial Officer |
|
2021-09-09 |
4 |
A |
$0.00 |
$0 |
D/D |
42,200 |
42,200 |
|
- |
|
Serafini Tito |
Chief Strategy Officer |
|
2021-09-09 |
4 |
A |
$0.00 |
$0 |
D/D |
42,200 |
42,200 |
|
- |
|
Courtney Phillips |
General Counsel & Secretary |
|
2021-09-09 |
4 |
A |
$0.00 |
$0 |
D/D |
35,500 |
35,500 |
|
- |
|
Greenberg Norman Michael |
Chief Scientific Officer |
|
2021-03-17 |
4 |
AS |
$16.73 |
$83,650 |
D/D |
(5,000) |
0 |
|
-55% |
|
Greenberg Norman Michael |
Chief Scientific Officer |
|
2021-03-17 |
4 |
OE |
$4.56 |
$24,050 |
D/D |
5,000 |
2,916 |
|
- |
|
Robinson William Hewitt |
Director |
|
2021-03-15 |
4 |
AS |
$16.89 |
$84,450 |
D/D |
(5,000) |
368,948 |
|
-58% |
|
Serafini Tito |
Chief Strategy Officer |
|
2021-03-11 |
4 |
AS |
$18.22 |
$183,130 |
I/I |
(10,000) |
353,875 |
|
-54% |
|
Greenberg Norman Michael |
Chief Scientific Officer |
|
2021-02-17 |
4 |
AS |
$18.95 |
$94,752 |
D/D |
(5,000) |
0 |
|
-52% |
|
Greenberg Norman Michael |
Chief Scientific Officer |
|
2021-02-17 |
4 |
OE |
$5.16 |
$25,800 |
D/D |
5,000 |
5,000 |
|
- |
|
Robinson William Hewitt |
Director |
|
2021-02-16 |
4 |
AS |
$19.07 |
$95,331 |
D/D |
(5,000) |
373,948 |
|
-53% |
|
Serafini Tito |
Chief Strategy Officer |
|
2021-02-11 |
4 |
AS |
$18.93 |
$189,272 |
I/I |
(10,000) |
363,875 |
|
-57% |
|
Greenberg Norman Michael |
Chief Scientific Officer |
|
2021-01-19 |
4 |
AS |
$15.21 |
$76,045 |
D/D |
(5,000) |
0 |
|
-42% |
|
Greenberg Norman Michael |
Chief Scientific Officer |
|
2021-01-19 |
4 |
OE |
$5.16 |
$25,800 |
D/D |
5,000 |
5,000 |
|
- |
|
Robinson William Hewitt |
Director |
|
2021-01-14 |
4 |
AS |
$15.06 |
$34,011 |
D/D |
(2,259) |
378,948 |
|
-45% |
|
Robinson William Hewitt |
Director |
|
2021-01-13 |
4 |
AS |
$15.05 |
$41,239 |
D/D |
(2,741) |
381,207 |
|
-44% |
|
Serafini Tito |
Chief Strategy Officer |
|
2021-01-11 |
4 |
AS |
$15.02 |
$150,192 |
I/I |
(10,000) |
373,875 |
|
-41% |
|
Greenberg Norman Michael |
Chief Scientific Officer |
|
2020-12-17 |
4 |
AS |
$16.61 |
$83,051 |
D/D |
(5,000) |
0 |
|
-28% |
|
Greenberg Norman Michael |
Chief Scientific Officer |
|
2020-12-17 |
4 |
OE |
$4.56 |
$22,800 |
D/D |
5,000 |
5,000 |
|
- |
|
Robinson William Hewitt |
Director |
|
2020-12-14 |
4 |
AS |
$16.67 |
$83,369 |
D/D |
(5,000) |
383,948 |
|
-26% |
|
Serafini Tito |
Chief Strategy Officer |
|
2020-12-11 |
4 |
AS |
$15.87 |
$158,735 |
I/I |
(10,000) |
383,875 |
|
-25% |
|
Greenberg Norman Michael |
Chief Scientific Officer |
|
2020-11-27 |
4 |
AS |
$15.34 |
$48,719 |
D/D |
(3,175) |
0 |
|
-22% |
|
Greenberg Norman Michael |
Chief Scientific Officer |
|
2020-11-27 |
4 |
OE |
$4.56 |
$14,478 |
D/D |
3,175 |
3,175 |
|
- |
|
Greenberg Norman Michael |
Chief Scientific Officer |
|
2020-11-17 |
4 |
AS |
$15.04 |
$27,448 |
D/D |
(1,825) |
0 |
|
-4% |
|
Greenberg Norman Michael |
Chief Scientific Officer |
|
2020-11-17 |
4 |
OE |
$4.56 |
$8,322 |
D/D |
1,825 |
1,825 |
|
- |
|
Serafini Tito |
Chief Strategy Officer |
|
2020-11-16 |
4 |
AS |
$15.12 |
$133,784 |
I/I |
(8,847) |
393,875 |
|
-7% |
|
132 Records found
|
|
Page 2 of 6 |
|
|